Epidemiology of colon cancer in Scandinavia.

Isr J Med Sci

Published: April 1979

The occurrence of colon cancer in four Scandinavian (Nordic) countries--Finland, Denmark, Norway and Sweden--is described. In addition, a number of correlations relevant to the etiology of colon cancer are presented. The observable differences in the risk for colon cancer among the Nordic countries can largely be accounted for by socioeconomic factors.

Download full-text PDF

Source

Publication Analysis

Top Keywords

colon cancer
16
epidemiology colon
4
cancer
4
cancer scandinavia
4
scandinavia occurrence
4
occurrence colon
4
cancer scandinavian
4
scandinavian nordic
4
nordic countries--finland
4
countries--finland denmark
4

Similar Publications

Objective: Addressing the rising cancer rates through timely diagnosis and treatment is crucial. Additionally, cancer survivors need to understand the potential risk of developing secondary cancer (SC), which can be influenced by several factors including treatment modalities, lifestyle choices, and habits such as smoking and alcohol consumption. This study aims to establish a novel relationship using linear regression models between dose and the risk of SC, comparing different prediction methods for lung, colon, and breast cancer.

View Article and Find Full Text PDF

Objective: This study aimed to develop a simple machine-learning model incorporating lymph node metastasis status with F-18 Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and clinical information for predicting regional lymph node metastasis in patients with colon cancer.

Methods: This retrospective study included 193 patients diagnosed with colon cancer between January 2014 and December 2017. All patients underwent F-18 FDG PET/CT and blood test before surgery.

View Article and Find Full Text PDF

Background And Aims: Probe-based confocal endomicroscopy (pCLE) allows real-time microscopic visualization of the intestinal mucosa surface layers. Despite remission achieved through anti-tumor necrosis factor or vedolizumab therapy, anomalies in the intestinal epithelial barrier are observed in inflammatory bowel disease (IBD) patients. Our study aimed to assess these abnormalities in non-IBD individuals and compare them with IBD patients in endoscopic remission to identify the associated factors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!